Inclusion Criteria:  Patient with symptomatic aortic stenosis due to severe native calcific aortic stenosis requiring aortic valve replacement and will undergo TAVI with the Edwards SAPIEN 3 System as part of standard-of-care treatment High or greater surgical risk The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.  Exclusion Criteria:  Medical, social, or psychological conditions that preclude appropriate consent and follow-up, including subjects under guardianship Considered to be part of a vulnerable population Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments Cannot tolerate an anticoagulation/antiplatelet regimen Evidence of intracardiac mass, thrombus, vegetation, active infection or endocarditis Tortuous or calcified vessels that would prevent safe entry of the dilators and sheath Participating in a drug or device study that has not reached its primary endpoint